PE20180023A1 - Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona - Google Patents

Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona

Info

Publication number
PE20180023A1
PE20180023A1 PE2016000848A PE2016000848A PE20180023A1 PE 20180023 A1 PE20180023 A1 PE 20180023A1 PE 2016000848 A PE2016000848 A PE 2016000848A PE 2016000848 A PE2016000848 A PE 2016000848A PE 20180023 A1 PE20180023 A1 PE 20180023A1
Authority
PE
Peru
Prior art keywords
treatment
hsdd
trazodone
bupropion
women
Prior art date
Application number
PE2016000848A
Other languages
English (en)
Inventor
Nick G Sitchon
Robert E Pyke
Robert Taylor Segraves
Anita Clayton
Leonard Derogatis
Molly Katz
Cindy Meston
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of PE20180023A1 publication Critical patent/PE20180023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a un metodo de tratamiento de una mujer con trastorno del deseo sexual hipoactivo (HSDD) que comprende: a) administracion diaria de un primer farmaco tal como bupropion que tiene una concentracion de dosis de 150 mg; b) administracion diaria de un segundo farmaco tal como trazodona que tiene una concentracion de dosis de 75 mg; y c) dicha administracion del primer y segundo farmaco se encuentra de acuerdo con un regimen de tratamiento prescrito para el tratamiento la mujer para HSDD
PE2016000848A 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona PE20180023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
PE20180023A1 true PE20180023A1 (es) 2018-01-09

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000848A PE20180023A1 (es) 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona

Country Status (9)

Country Link
KR (1) KR20170142797A (es)
AR (2) AR105087A1 (es)
AU (1) AU2016204151A1 (es)
CA (1) CA2933921A1 (es)
CL (1) CL2016001597A1 (es)
MX (1) MX2016008272A (es)
PE (1) PE20180023A1 (es)
UY (1) UY36742A (es)
WO (1) WO2017218018A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
EP2879680A4 (en) * 2012-08-06 2016-06-01 S1 Biopharma Inc TREATMENT REGIMES

Also Published As

Publication number Publication date
KR20170142797A (ko) 2017-12-28
CA2933921A1 (en) 2017-12-17
AU2016204151A1 (en) 2018-01-18
AR105047A1 (es) 2017-08-30
WO2017218018A1 (en) 2017-12-21
MX2016008272A (es) 2017-12-18
UY36742A (es) 2016-12-30
CL2016001597A1 (es) 2017-10-06
AR105087A1 (es) 2017-09-06

Similar Documents

Publication Publication Date Title
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
ECSP18024971A (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma
ECSP17014159A (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
PE20180023A1 (es) Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
CL2014003326A1 (es) Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.
CL2018003184A1 (es) Una composición inmunogénica para el tratamiento del cáncer y métodos para preparar la misma
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados
AR092169A1 (es) Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
PE20170201A1 (es) Formas de dosificacion farmaceutica
AR116417A1 (es) COMBINACIONES DE INHIBIDORES DE TGFb E INHIBIDORES DE CDK PARA TRATAMIENTOS CONTRA EL CÁNCER
UA105323U (uk) Спосіб лікування курей, хворих на змішану нематодозно-цестодозну інвазію